NASDAQ:FBLG FibroBiologics (FBLG) Stock Price, News & Analysis $2.70 +0.10 (+3.85%) (As of 10/14/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About FibroBiologics Stock (NASDAQ:FBLG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get FibroBiologics alerts:Sign Up Key Stats Today's Range$2.52▼$2.7450-Day Range$1.11▼$3.8952-Week Range$1.08▼$55.00Volume87,875 shsAverage Volume266,886 shsMarket Capitalization$96.44 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingStrong Buy Company OverviewFibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.Read More… This Crypto Is Set to Explode in October (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW FibroBiologics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks63rd Percentile Overall ScoreFBLG MarketRank™: FibroBiologics scored higher than 63% of companies evaluated by MarketBeat, and ranked 523rd out of 1,015 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingFibroBiologics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageFibroBiologics has only been the subject of 2 research reports in the past 90 days.Read more about FibroBiologics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for FibroBiologics are expected to grow in the coming year, from ($0.37) to ($0.29) per share.Price to Book Value per Share RatioFibroBiologics has a P/B Ratio of 67.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about FibroBiologics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.38% of the float of FibroBiologics has been sold short.Short Interest Ratio / Days to CoverFibroBiologics has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in FibroBiologics has recently increased by 21.62%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFibroBiologics does not currently pay a dividend.Dividend GrowthFibroBiologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.38% of the float of FibroBiologics has been sold short.Short Interest Ratio / Days to CoverFibroBiologics has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in FibroBiologics has recently increased by 21.62%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News Sentiment0.94 News SentimentFibroBiologics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for FibroBiologics this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for FBLG on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows7 people have added FibroBiologics to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, FibroBiologics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $35,235.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.80% of the stock of FibroBiologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about FibroBiologics' insider trading history. Receive FBLG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FibroBiologics and its competitors with MarketBeat's FREE daily newsletter. Email Address FBLG Stock News HeadlinesFibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual SummitOctober 11, 2024 | globenewswire.comFibroBiologics (NASDAQ:FBLG) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…October 15, 2024 | Timothy Sykes (Ad)FibroBiologics to Present at 2024 Cell & Gene Meeting on the MesaSeptember 30, 2024 | globenewswire.comBionomics Limited (B1N0.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comFIBROBIOLOGICS INC. (SG0.BE)September 19, 2024 | nz.finance.yahoo.comFibroBiologics Engages Southern Star Research as CRO in AustraliaSeptember 19, 2024 | globenewswire.comFibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based TechnologySeptember 12, 2024 | globenewswire.comSee More Headlines FBLG Stock Analysis - Frequently Asked Questions How have FBLG shares performed this year? FibroBiologics' stock was trading at $17.75 at the beginning of the year. Since then, FBLG shares have decreased by 84.8% and is now trading at $2.70. View the best growth stocks for 2024 here. How were FibroBiologics' earnings last quarter? FibroBiologics, Inc. (NASDAQ:FBLG) posted its earnings results on Wednesday, August, 7th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). When did FibroBiologics IPO? FibroBiologics (FBLG) raised $144 million in an initial public offering (IPO) on Wednesday, January 31st 2024. The company issued 4,806,226 shares at a price of $30.00 per share. How do I buy shares of FibroBiologics? Shares of FBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of FibroBiologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that FibroBiologics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Netflix (NFLX). Company Calendar Last Earnings8/07/2024Today10/14/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FBLG Previous SymbolNASDAQ:FBLG CUSIPN/A CIK1958777 Webwww.fibrobiologics.com Phone281-671-5150FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+344.4%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.64 Quick Ratio0.64 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book67.50Miscellaneous Outstanding Shares35,719,000Free Float27,846,000Market Cap$96.44 million OptionableN/A BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:FBLG) was last updated on 10/15/2024 by MarketBeat.com Staff From Our PartnersNo matter the outcome of the election, it could be a death sentence for your wealth...In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional inv...Allegiance Gold | SponsoredThe Masterworks of Cars - MCQ MarketsMCQ Markets is launching a new innovative platform that allows car enthusiasts to be able to invest in fractio...Issuance Express | SponsoredThis Crypto Is Set to Explode in OctoberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI Detects Profit Surge On MondayThis has given investors the opportunity to beat the market by 1,700% and a 100% win rate to begin the year.Monument Traders Alliance | SponsoredElon tried to warn youI know most people will ignore this dire and urgent warning. They’ll say it can’t happen here, not in America.Porter & Company | SponsoredHave you heard of Donald Trump’s Project Crypto?Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredUnlock This Opportunity Before October 22nd: Discover Elon Musk's Latest AI Device!This is Elon Musk's latest AI innovation… According to Eric Fry, a seasoned expert with 30 years of experie...InvestorPlace | SponsoredFREE investing Class TOMORROW + 2 FREE BonusesOver the last 37 years on Wall Street, I've developed a unique investing strategy that allows me to find stock...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroBiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroBiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.